The Patient-Reported Experience Measure for Improving qUality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy by Fernandes S, Fond G, Zendjidjian X, Michel P, Baumstarck K, Lancon C, Berna F, Schurhoff F, Aouizerate B, Henry C, Etain B, Samalin L, Leboyer M, Llorca PM, Coldefy M, Auquier P, Boyer L

“…The aims of this project are 1) to develop item banks of PREMs that assess the quality of health care for adult patients with psychiatric disorders (schizophrenia, bipolar disorder, and depression) and to validate computerized adaptive testing (CAT) to support the routine use of PREMs; and 2) to analyze the implementation and acceptability of the CAT among patients, professionals, and health authorities.Methods: This multicenter and cross-sectional study is based on a mixed method approach, integrating qualitative and quantitative methodologies in two main phases: 1) item bank and CAT development based on a standardized procedure, including conceptual work and definition of the domain mapping, item selection, calibration of the item bank and CAT simulations to elaborate the administration algorithm, and CAT validation; and 2) a qualitative study exploring the implementation and acceptability of the CAT among patients, professionals, and health authorities.Discussion: The development of a set of PREMs on quality of care in mental health that overcomes the limitations of previous works (ie, allowing national comparisons regardless of the characteristics of patients and care and based on modern testing using item banks and CAT) could help health care professionals and health system policymakers to identify strategies to improve the quality and efficiency of mental health care.Trial registration: NCT02491866. …”
Get full text

The Unhappy Mental Health Triad: Comorbid Severe Mental Illnesses, Personality Disorders, and Substance Use Disorders in Prison Populations by Adrian P. Mundt, Adrian P. Mundt, Gergő Baranyi

“…Diagnoses were a priori grouped as SMI including psychosis, bipolar disorder and major depression, PD including borderline and antisocial PD and SUD including alcohol and drug abuse or dependence. …”
Get full text

Converging roles of neurodevelopment and Wnt signaling in neuropsychiatric disorders by Durak, Omer

Get full text

Mouse mutants in schizophrenia risk genes GRIN2A and AKAP11 show EEG abnormalities in common with schizophrenia patients by Herzog, Linnea E, Wang, Lei, Yu, Eunah, Choi, Soonwook, Farsi, Zohreh, Song, Bryan J, Pan, Jen Q, Sheng, Morgan

“…AKAP11 and GRIN2A mutations are also associated with bipolar disorder [2], and epilepsy and developmental delay/intellectual disability [1, 3, 4], respectively. …”
Get full text

Lurasidone for the treatment of bipolar depression: an evidence-based review by Deckersbach, Thilo, Widge, Alik, Franklin, Rachel, Zorowitz, Sam, Corse, Andrew

“…Bipolar disorder (BD) is a debilitating and difficult-to-treat psychiatric disease that presents a serious burden to patients’ lives as well as health care systems around the world. …”
Get full text
Get full text

Group-personalized regression models for predicting mental health scores from objective mobile phone data streams: observational study by Palmius, N, Saunders, K, Carr, O, Geddes, J, Goodwin, G, De Vos, M

“…Participants were diagnosed with bipolar disorder (n=20); borderline personality disorder (n=17); or were healthy controls (n=22). …”

Development and initial evaluation of a behavioural intervention to support weight management for people with serious mental illness: an uncontrolled feasibility and acceptability... by Lee, C, Waite, F, Piernas Sanchez, C, Aveyard, P

“…<p><strong>Background:</strong>&nbsp;The rates of obesity and associated health problems are higher in people with serious mental illness (SMI), such as schizophrenia and bipolar disorder, than the general population. A primary care referral to a behavioural weight management programme can be an effective intervention, but people with SMI have reported barriers to engaging with them and bespoke options are rarely provided in routine practice. …”

Haloperidol alone or in combination for acute mania. by Cipriani, A, Rendell, J, Geddes, J

“…SELECTION CRITERIA: Randomised trials comparing haloperidol with placebo or other active treatment in the treatment of acute manic or mixed episodes in patients with bipolar disorder or schizoaffective disorder. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. …”

Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study) by Azim, L, Hindmarch, P, Browne, G, Chadwick, T, Clare, E, Courtney, P, Dixon, L, Duffelen, N, Fouweather, T, Geddes, JR, Goudie, N, Harvey, S, Helter, T, Holstein, E-M, Martin, G, Mawson, P, McCaffery, J, Morriss, R, Simon, J, Smith, D, Stokes, PRA, Walker, J, Weetman, C, Wolstenhulme, F, Young, AH, Watson, S, McAllister-Williams, RH

“…<p><strong>Background:</strong> Treatment Resistant Bipolar Depression (TRBD) is a major contributor to the burden of disease associated with Bipolar Disorder (BD). Treatment options for people experiencing bipolar depression are limited to three interventions listed by National Institute for Health and Care: lamotrigine, quetiapine and olanzapine, of which the latter two are often not well tolerated. …”

Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders by Colbourne, C, Harrison, PJ

“…We created cohorts of patients who, prior to first CCB exposure, either had to have, or could not have had, a recorded ICD-10 diagnosis in any of the following categories: psychotic disorder; affective disorder (including bipolar disorder and major depressive disorder); anxiety disorder; substance use disorder; sleep disorder; delirium; dementia, or movement disorder. …”

Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. by Geddes, J, Goodwin, G, Rendell, J, Azorin, J, Cipriani, A, Ostacher, M, Morriss, R, Alder, N, Juszczak, E

“…BACKGROUND: Lithium carbonate and valproate semisodium are both recommended as monotherapy for prevention of relapse in bipolar disorder, but are not individually fully effective in many patients. …”

Antipsychotics, mood stabilisers, and risk of violent crime. by Fazel, S, Zetterqvist, J, Larsson, H, Långström, N, Lichtenstein, P

“…However, we identified potentially important differences by diagnosis-mood stabilisers were associated with a reduced rate of violent crime only in patients with bipolar disorder. The rate of violence reduction for antipsychotics remained between 22% and 29% in sensitivity analyses that used different outcomes (any crime, drug-related crime, less severe crime, and violent arrest), and was stronger in patients who were prescribed higher drug doses than in those prescribed low doses. …”

An online supported self-management toolkit for relatives of people with psychosis or bipolar experiences: the IMPART multiple case study by Fiona Lobban, Duncan Appelbe, Victoria Appleton, Golnar Aref-Adib, Johanna Barraclough, Julie Billsborough, Naomi R Fisher, Sheena Foster, Bethany Gill, David Glentworth, Chris Harrop, Sonia Johnson, Steven H Jones, Tibor Z Kovacs, Elizabeth Lewis, Barbara Mezes, Charlotte Morton, Elizabeth Murray, Puffin O’Hanlon, Vanessa Pinfold, Jo Rycroft-Malone, Ronald Siddle, Jo Smith, Chris J Sutton, Pietro Viglienghi, Andrew Walker, Catherine Wintermeyer

“…Objectives: Use the implementation of the Relatives’ Education And Coping Toolkit (REACT) for psychosis/bipolar disorder to identify critical factors affecting uptake and use, and develop an implementation plan to support the delivery of REACT. …”
Get full text

Impact of serious mental illness on the treatment and mortality of older patients with locoregional high‐grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 ... by Dennis A. Fried, Hossein Sadeghi‐Nejad, Dian Gu, Shouhao Zhou, Weiguo He, Sharon H. Giordano, Sri Ram Pentakota, Kitaw Demissie, Drew Helmer, Chan Shen

“…Preexisting SMI was identified by claims indicative of bipolar disorder, schizophrenia, and other psychotic disorder, during the 2 years before cancer diagnosis. …”
Get full text

Causal atlas between inflammatory bowel disease and mental disorders: a bi-directional 2-sample Mendelian randomization study by Xiaorong Yang, Xiaorong Yang, Xiaorong Yang, Xiaorong Yang, Lejin Yang, Tongchao Zhang, Hong Zhang, Hong Zhang, Hong Zhang, Hui Chen, Xiuli Zuo, Xiuli Zuo, Xiuli Zuo

“…In addition, we found that bipolar disorder and schizophrenia could increase the odds of IBD, with OR values of 1.138 (95%CI: 1.084-1.194; P=1.9×10-7), and 1.115 (95%CI: 1.071-1.161; P=1.12×10-7), respectively. …”
Get full text

Biomedical and candidate SN P markers of chronopathologies can significantly change affinity of ТАТА -binding protein for human gene promoters by D. A. Rasskazov, N. L. Podkolodnyy, O. A. Podkolodnaya, N. N. Podkolodnaya, V. V. Suslov, L. K. Savinkova, P. M. Ponomarenko, M. P. Ponomarenko

“…In the [–70; –20] region of promoters of 14 human genes (location of proven binding sites of ТВР), we found 32 known and candidate SNP markers of circadian- rhythm disturbances, including rs17231520 and rs569033466 (both: risk of chronopathologies in liver); rs35036378 (behavioral chronoaberrations); rs549858786 (rheumatoid arthritis with a chronoaberration of IL1B expression); rs563207167, rs11557611, and rs5505 (all three: chronopathologies of the tumor – host balance, blood pressure, and the reproductive system); rs1143627 (bipolar disorder with circadian dependence of diagnosis and treatment); rs16887226 and rs544850971 (both: lowered resistance to endotoxins because of the imbalance between the circadian and immune systems); rs367732974 and rs549591993 (both: circadian dependence of heart attacks); rs563763767 (circadian dependence of myocardial infarction); rs2276109 and rs572527200 (both: circadian dependence of asthma attacks); rs34223104, rs563558831, and rs10168 (circadian optima of treatment with methotrexate and cyclophosphamide); and rs397509430, rs33980857,rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: neurosensory hearing loss and restless legs syndrome). …”
Get full text

Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials by Dongyu Kang, Dongyu Kang, Dongyu Kang, Dongyu Kang, Dongyu Kang, Zhihui Jing, Zhihui Jing, Zhihui Jing, Zhihui Jing, Zhihui Jing, Ranran Li, Ranran Li, Ranran Li, Ranran Li, Ranran Li, Gangrui Hei, Gangrui Hei, Gangrui Hei, Gangrui Hei, Gangrui Hei, Tiannan Shao, Tiannan Shao, Tiannan Shao, Tiannan Shao, Tiannan Shao, Li Li, Li Li, Li Li, Li Li, Li Li, Mengxi Sun, Mengxi Sun, Mengxi Sun, Mengxi Sun, Mengxi Sun, Ye Yang, Ye Yang, Ye Yang, Ye Yang, Ye Yang, Ying Wang, Ying Wang, Ying Wang, Ying Wang, Ying Wang, Xiaoyi Wang, Xiaoyi Wang, Xiaoyi Wang, Xiaoyi Wang, Xiaoyi Wang, Yujun Long, Yujun Long, Yujun Long, Yujun Long, Yujun Long, Xiansheng Huang, Renrong Wu, Renrong Wu, Renrong Wu, Renrong Wu, Renrong Wu, Renrong Wu

“…A total of 67 people with schizophrenia or bipolar disorder treated with antipsychotics were assigned to 36 mg day−1 betahistine (n = 13) or 1,000 mg day−1 metformin (n = 25) or placebo (n = 29) treatment for 12 weeks, with evaluation at baseline and week 12. …”
Get full text

Association of hospitalization with structural brain alterations in patients with affective disorders over nine years by Katharina Förster, Dominik Grotegerd, Katharina Dohm, Hannah Lemke, Verena Enneking, Susanne Meinert, Ronny Redlich, Walter Heindel, Jochen Bauer, Harald Kugel, Thomas Suslow, Patricia Ohrmann, Angela Carballedo, Veronica O’Keane, Andrew Fagan, Kelly Doolin, Hazel McCarthy, Philipp Kanske, Thomas Frodl, Udo Dannlowski

“…These effects of hospitalization remained stable in a smaller sample excluding patients with bipolar disorder. PAD show gray matter volume decline in temporo-limbic regions over nine years. …”
Get full text

Effective Antidepressant Chronotherapeutics (Sleep Deprivation and Light Therapy) Normalize the IL-1β:IL-1ra Ratio in Bipolar Depression by Francesco Benedetti, Francesco Benedetti, Sara Dallaspezia, Sara Dallaspezia, Elisa Maria Teresa Melloni, Elisa Maria Teresa Melloni, Cristina Lorenzi, Raffaella Zanardi, Raffaella Zanardi, Barbara Barbini, Barbara Barbini, Cristina Colombo, Cristina Colombo

“…Here we explored the effects of TSD+LT on IL-1β signaling.MethodsWe studied the ratio between IL-1β and its receptor antagonist (IL-1β:IL1ra) in 33 healthy participants, and in 26 inpatients with a major depressive episode in course of Bipolar Disorder, before and after treatment with three cycles of repeated TSD+LT, interspersed with sleep recovery nights, administered during 1 week. …”
Get full text

Quality of life and mood disorders by N. Smaoui, I. Lajmi, A. Guermazi, S. Omri, R. Feki, M. Maalej Bouali, N. Charfi, J. Ben Thabet, L. Zouari, M. Maalej

“… Introduction Many researches addressing quality of life (QOL) has been demonstrated its impairment during acute episodes of bipolar disorder (BD) and major depressive disorder (MDD). …”
Get full text